(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Why some African countries are prone to military takeovers- Linda Hamilton, 69, says she doesn't want to 'chase longevity'
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Hezbollah claims right to respond to killing of top commander
